| Literature DB >> 10523073 |
T Giverhaug1, T Loennechen, J Aarbakke.
Abstract
The antimetabolites 6-mercaptopurine (6-MP) and methotrexate (MTX) are the cornerstones in the maintenance treatment of children's acute lymphoblastic leukemia (ALL). The biochemical mechanisms underlying the increased therapeutic efficacy of the combination of these drugs have not yet been elucidated. However, both drugs interact with important pathways. such as purine de novo synthesis (PDNS), purine salvage, and methylation reactions. A review of the mechanistic aspects of the interactions between 6-MP and MTX is given.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10523073 DOI： 10.1016/s0306-3623(99)00022-1
Source DB: PubMed Journal: Gen Pharmacol ISSN： 0306-3623